Apogee Therapeutics Inc.
Apogee Therapeutics Reports Third Quarter 2024 Financial Results and Pipeline Progress
Summary
Apogee Therapeutics, Inc. announced its financial results for the third quarter of 2024, reporting a net loss of $49.0 million, an increase from the $20.8 million loss in the same period of 2023. The company attributed the increase to higher research and development (R&D) and general and administrative (G&A) expenses, partially offset by higher interest income. R&D expenses rose to $45.7 million from $17.1 million, while G&A expenses increased to $13.0 million from $7.2 million. Apogee also highlighted pipeline progress, including positive results from the APG777 Phase 1 trial and plans to report interim Phase 1 data for APG808 in 4Q 2024 and for APG990 in 1H 2025. The company ended the quarter with $754 million in cash, cash equivalents, and marketable securities, providing a runway into 2028.
Profitelligence Alerts
Get alerts for APGE
Be first to know when Apogee Therapeutics Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Apogee Therapeutics Inc.
Apogee Therapeutics Inc. is a biotechnology company focused on the development of biologic therapies for atopic dermatitis and other inflammatory diseases. The primary purpose of Apogee Therapeutics is to leverage its expertise in immunology and protein engineering to address unmet needs in the treatment of autoimmune and inflammatory conditions. The company is active in sectors such as healthcare and pharmaceuticals, contributing to advancements in medical biotechnology. Apogee Therapeutics plays a significant role in the financial market by advancing cutting-edge therapies in the biopharmaceutical landscape. It engages in research and development efforts to bring innovative biologic medicines to patients, thereby impacting the broader pharmaceutical industry. The company's focus on treating inflammatory diseases aligns with an increasing demand for novel treatments arising from a greater understanding of disease mechanisms and patient needs. By developing specialized biologic solutions, Apogee Therapeutics positions itself as a key player in addressing some of the challenges associated with chronic inflammatory conditions, ultimately pushing forward the boundaries of therapeutic options available to patients worldwide.
Official SEC Documents
Advertisement